LogicBio Therapeutics Inc
NASDAQ:LOGC
| Market Cap (Intraday) | 9.00M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $0.34 |
| 50-Day MA | $0.41 |
| 200-Day MA | $0.84 |
LogicBio Therapeutics Inc Stock, NASDAQ:LOGC
65 Hayden Avenue, 2nd floor, Lexington, Massachusetts 02421
United States of America
Phone: +1.617.245.0399
Number of Employees: 62
Description
LogicBio Therapeutics, Inc. engages in the development of a genome editing technology platform. It focuses on the commercialization of GeneRide, which enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination. Its pipeline includes LB-001, LB-301 and LB-401. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Lexington, MA.